About 400,000 people in Europe live with Pulmonary Fibrosis and some 100,000 patients die each year from the disease. The most common type of PF is IPF (Idiopathic Pulmonary Fibrosis), accounting for 200,000 patients in Europe. EU-IPFF, the European Patient… Continue reading IPF awareness month
Sandra Ekstedt has joined Oxcia as Senior Scientist, a very welcome reinforcement as Sandra has a strong background in inflammation, immunology and airway disease with a PhD and over 10 years of work in the field. Sandra will primarily work… Continue reading Oxcia welcomes Senior Scientist Sandra Ekstedt
Oxcia is happy about all productive meetings and insightful discussions with pharma and investors at the LSX Nordic Congress. If you missed the congress and want to learn more about Oxcia and our exciting projects, please get in touch or… Continue reading LSX Nordic Congress
The 1st of September William Stafford, PhD joined Oxcia AB as Translational Director. William has a background in oncology and redox-biology from the Karolinska Institutet. He developed his PhD work toward commercialization through Karolinska Institutet Innovations AB, leading to an… Continue reading Translational Director strengthens Oxcia’s team
Oxcia will be meeting potential partners and investors at the LSX Nordic Congress for Nordic Life Science next week. Please get in contact if you are there and want to meet.
There was a lot of interest in Oxcias poster describing OXC-201, the promising novel treatment strategy for Idiopathic pulmonary fibrosis (IPF), at the IPF summit in Boston 29th of August to 1st of September. A new treatment is desperately needed.… Continue reading Large interest in OXC-201 at the IPF Summit in Boston
Christina Kalderén from Oxcia will present a poster on OXC-201 at the 6th IPF Summit in Boston, 29th of August to 1st of September. The poster title is “Inhibiting OGG1, a novel strategy for treatment of IPF, blocking inflammatory and… Continue reading Oxcia attending IPF Summit in Boston
Oxcia AB är ett mindre innovativt företag som är inriktad på forskning och utveckling av nya behandlingar mot cancer och inflammations- och fibrosrelaterade sjukdomar. Bolaget arbetar inom teknikplattformen DNA Damage Response och oxidativ stress. Genom att hindra kroppens processer att… Continue reading Chief financial officer (deltid)
Oxcia AB is pioneering novel DNA Damage Response (DDR) and oxidative stress target drug development, researching solutions for patients suffering from diseases caused by cancer and inflammation. The company’s product portfolio consists of two drug candidates, of which one is… Continue reading Translational Scientist/Director to Oxcia AB
Watch the presentation from the webinar.